The diaTribe Foundation invites you to the 5th Annual Musings Under the Moon: Applying Revelations from COVID-19
Join us to hear the brightest and most innovative leaders in diabetes technology and therapy share their insights and ideas on the future of the field. Along with forward-thinking dialogue, this series of events will feature opportunities to connect with other attendees virtually.
In our first panel on May 11th, we explored opportunities for personalizing health care in the shadow of the massive virtual revolution at our fingertips. We learned from expert panelists with hundreds of individuals across the world, some of whom had never met someone else living with diabetes. Through open chat rooms available to the audience before and after the event, the power of community and learning from others’ lived experiences shined.
We look forward to seeing you on June 5th for our second Musings Under the Moon discussion of the year. Please spread the word and share this event with anyone interested in learning more about how COVID-19 shaping the way we think about the future of diabetes care. This year, Musings tickets will be complimentary thanks to the generous contributions of our sponsors. We welcome anyone interested in learning about the massive shifts and opportunities occurring in the world of diabetes. Join the conversation on Twitter with #diaTribeMusings.
Submit questions for the panelists here.
The Law of Inertia during a Global Pandemic: What's Here to Stay and What's Next in Diabetes Care
June 5th, 10-11:30am PT / 1-2:30pm ET
The pandemic has dramatically altered our routines, forcing us to evaluate what is working, and what needs to start working, to better the health of our nation and world. In many ways, the future of health care is being built right now – how do we ensure that these new systems embrace the newest diabetes technology and therapy innovations? Join us to learn from expert leaders in therapy and medical devices about what is on the horizon for people living with diabetes.
Our highly-regarded speakers are AstraZeneca Vice President of Cardiovascular and Metabolic Disease Kiersten Combs, Medtronic Executive Vice President of Diabetes Sean Salmon, and Sanofi Global Head of Integrated Care Chris Boulton. The panel will be moderated by diaTribe Founder Kelly Close and diaTribe Senior Associate Divya Gopisetty. See their detailed bios below.
Chris Boulton is currently the Global Head of Integrated Care at Sanofi, focused on digital solutions in the field of diabetes. The goal of Sanofi Integrated Care is to deliver digital tools and technologies that support patients, clinicians and payers to better manage diabetes through patient support, data generation and value creation. Chris has worked for 24 years in the pharmaceutical industry, covering multiple roles, therapy areas, and geographies. Previously, Chris led the global commercial launch preparation for a product in diabetes, led large commercial teams at a country level, and worked in a number of strategic business roles. Chris has been fortunate to live and work in the US, in Europe and in Australia, working in both big pharmaceutical companies as well as start-up.
Kiersten leads the overall US Cardiovascular & Metabolic Disease (US CVMD) team at AstraZeneca and is responsible for the strategic direction, selling strategy and performance of the cardiovascular and diabetes business units. During her 15 years with AstraZeneca, Kiersten has served in various roles across many areas of the business, both in the US and globally, starting in supply chain and commercial operations. She has held marketing leadership roles for BRILINTA, CRESTOR, and EPANOVA and has held sales leadership roles in the both the Respiratory and Diabetes organizations. Most recently, Kiersten was Global Vice President, roxadustat, where she was responsible for setting the global strategy for the launch and commercialization of roxadustat, including working to support regions and key markets in setting and executing launch strategies.
Sean Salmon serves as Executive Vice President and Group President for the Medtronic Diabetes Group. In this role, Sean is responsible for the overall strategic direction of the business and its day-to-day global operations. Sean joined Medtronic in 2004 and has held increasingly senior management roles. Most recently as President of Coronary & Structural Heart within our Cardiac & Vascular Group, he led numerous functions including Clinical, Regulatory, R&D, Quality, Health Economics & Reimbursement, Business Development and Strategy. He led Medtronic’s entry into the highly-competitive drug eluting stent market and subsequently diversified the business via organic innovation and acquisitions. He also led the expansion of Medtronic’s fast-growing transcatheter valve replacement (TAVR) business by commercializing multiple product innovations, extending global penetration and by expanding treatment indications. Sean has nearly 30 years’ experience in the medical device and pharmaceutical industries, with previous roles at CR Bard, Johnson & Johnson, SurgiVision and EuroRSCG Life. He earned an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.